Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 1.00 |
| ▸ | ERCC1 | P07992 | 3/20 | 0.53 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775534 | 0.91 | P2RX7 (1.00) | P2RX7ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL2774977 | 0.90 | P2RX7 (1.00) | P2RX7ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL2775593 | 0.90 | P2RX7 (1.00) | P2RX7ERCC1ERCC4 | |
| SCHEMBL2775455 | 0.88 | P2RX7 (0.85) | P2RX7 | |
| SCHEMBL2774095 | 0.82 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL2777099 | 0.81 | P2RX7 (1.00) | P2RX7ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL2776441 | 0.80 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL2773323 | 0.79 | P2RX7 (0.82) | P2RX7 | |
| SCHEMBL2778200 | 0.75 | P2RX7 (0.83) | P2RX7 | |
| SCHEMBL17914676 | 0.74 | ALDH1A1 (0.62) | P2RX7ERCC1ERCC4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056595-A1 | Pyrazole Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | claimed |
| US-20100056595-A1 | Pyrazole Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056595-A1 | Pyrazole Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056595-A1 | Pyrazole Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2008125600-A2 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056595-A1 | Pyrazole Derivatives as P2X7 Modulators | P2RX3, P2RX6, P2RX7 | P2RX7 3/4885ERCC1 3358/4885ERCC4 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.